Comparing gonadotrophin-releasing hormone agonists or gonadotrophin-releasing hormone antagonists in poor responder in IVF

نویسنده

  • Fatma Aletebi
چکیده

Objective: The use of GnRH antagonist versus GnRH agonist in poor responder for patient undergoing ovarian hyperstimulation and in vitro-fertilization was compared. Materials and Methods: In this study, 23 patients underwent ovarian hyperstimulation with recombinant FSH followed by the use of GnRH antagonist (Cetrorelix) 0.25mg during the late Follicular Phase. These patients were compared to 20 patients who underwent controlled ovarian hyper-stimulation with recombinant FSH proceeded by GnRH agonist (short protocol). Results: There was no significant difference between the two groups for mean-age, duration of infertility or base line FSH, number of ampoules of gonadotrophin used, number of mature oocyte retrieved, estradiol concentration on the day of injection of human chronic gonadotrophin HCG, fertilization rate and number of embryo transferred. The clinical pregnancy rate in the antagonist group appear to be high but not significantly different (12% compared to 10%). Conclusion: The addition of GnRH antagonist to ovarian stimulation protocol may be used for poor responder. Further randomized clinical studies with large sample size required to elicit significant differences.

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

The effect of equine chorionic gonadotrophin (ecg) injection combined with prostaglandin F2α (pGF2α) and gonadotrophin releasing hormone (GnRH) treatment on reproductive performance of Zandi ewes during non-breeding season

In this study, we aimed to investigate reproductive performance in estrus-induced Zandi ewes treated with equine chorionic gonadotrophin (eCG) injection in combination with prostaglandin F2α (PGF2α)and gonadotrophin releasing hormone (GnRH) during non-breeding season. The estrous cycle was synchronized using controlled internal drug release (CIDR) for 12 days. The ewes were randomly assigned to...

متن کامل

Induction of the endogenous gonadotrophin surge for oocyte maturation with intra-nasal gonadotrophin-releasing hormone analogue (buserelin): effective minimal dose.

From 1985-1987, a total of 34 couples undergoing superovulation for a single in-vitro fertilization (IVF) cycle with clomiphene citrate and purified follicle stimulating hormone (FSH) or human menopausal gonadotrophin (HMG) were randomly allocated doses of intra-nasal buserelin to induce an endogenous gonadotrophin surge, prior to oocyte collection. The doses ranged from a single 25 microg dose...

متن کامل

Effects of gonadotrophin releasing hormone analogues on human endometrial stromal cells and embryo invasion in vitro.

BACKGROUND Gonadotrophin releasing hormone (GnRH) analogues are widely used in IVF programmes as a method of suppressing the luteinizing hormone (LH) surge prior to ovarian stimulation, but their roles outside the pituitary remain relatively unknown. A 2002 Cochrane review (Al-Inany et al. Gonadotrophin-releasing hormone antagonists for assisted conception. Cochrane Database Syst Rev 2006;3:CD0...

متن کامل

Luteal Supplementation with Estradiol and Progesterone in Patients Stimulated with GnRH Antagonist/rFSH for IVF

The use of progesterone for luteal support in stimulated cycles for in-vitro fertilization is well established. However, the benefits of the addition of estradiol are still controversial. The aim of this study was to compare ongoing pregnancy rates in patients stimulated with recombinant follicle stimulating hormone and gonadotrophin releasing hormone antagonist for in vitro fertilization, who ...

متن کامل

Pharmacological treatment of patients with advanced prostate cancer.

Prostate cancer is linked to the male sex hormone testosterone. In advanced disease, blocking the production of testosterone using androgen deprivation therapy causes regression of prostate cancer and minimises or prevents symptoms associated with the disease. Luteinising hormone-releasing hormone agonists are commonly used in the management of prostate cancer, however less is known about the r...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

عنوان ژورنال:

دوره   شماره 

صفحات  -

تاریخ انتشار 2007